Background: Neuroblastoma is the most common pediatric malignancy with heterogeneous clinical behaviors, ranging from spontaneous regression to aggressive progression. Many studies have identified aberrations related to the pathogenesis and prognosis, broadly classifying neuroblastoma patients into high-and low-risk groups, but predicting tumor progression and clinical management of high-risk patients remains a big challenge. Results: We integrate gene-level expression, array-based comparative genomic hybridization and functional gene-interaction network of 145 neuroblastoma patients to detect potential driver genes. The drivers are summarized into a driver-gene score (DGscore) for each patient, and we then validate its clinical relevance in terms of association with patient survival. Focusing on a subset of 48 clinically defined high-risk patients, we identify 193 recurrent regions of copy number alterations (CNAs), resulting in 274 altered genes whose copy-number gain or loss have parallel impact on the gene expression. Using a network enrichment analysis, we detect four common driver genes, ERCC6, HECTD2, KIAA1279, EMX2, and 66 patient-specific driver genes. Patients with high DGscore, thus carrying more copy-number-altered genes with correspondingly up-or down-regulated expression and functional implications, have worse survival than those with low DGscore (P = 0.006). Furthermore, Cox proportional-hazards regression analysis shows that, adjusted for age, tumor stage and MYCN amplification, DGscore is the only significant prognostic factor for high-risk neuroblastoma patients (P = 0.008). Conclusions: Integration of genomic copy number alteration, expression and functional interaction-network data reveals clinically relevant and prognostic putative driver genes in high-risk neuroblastoma patients. The identified putative drivers are potential drug targets for individualized therapy.
[1]Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai, Peoples R China;
[2]Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China;
[3]Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, Shanghai, Peoples R China;
[4]Karolinska Inst, Dept Med Epidemiol & Biostat, Box 281,Nobels Vag 12A, S-17177 Stockholm PO, Sweden
(8.0+极速模式)